Caszyme CEO Says CRISPR Gene Editing Could Help Patients, Save The Planet
Executive Summary
Caszyme CEO and 2022 In Vivo Rising Leader Monika Paule is on a mission to expand the CRISPR toolbox of available proteins to enhance diagnostic tools, therapeutics and even agricultural practices.
You may also be interested in...
EIP And Diffusion Combine To Form CNS Firm With Dementia Focus
The US biotechs are joining forces to form a new, listed company with sufficient cash to advance EIP’s potentially disease-modifying drug candidate through Phase II development in dementia with Lewy bodies, which presents a high unmet need.
Executives On The Move: Applied Molecular Transport, Alimera Sciences and More
Recent executive changes in the industry include C-suite changes at Exicure and Applied Molecular Transport. Meanwhile, new directors were appointed at Immunotech Biopharm and Alimera Sciences.
ThirtyFiveBio Makes Its Debut With First-In-Class GPR35 Antagonist Approach
Emerging Company Profile: Backed by $20m in seed funding, the UK firm is going against the grain by antagonizing, instead of agonizing, G protein-coupled receptor 35 with an eye to treating colorectal cancer and other gastrointestinal conditions.